Stifel Nicolaus Boosts Zoetis (NYSE:ZTS) Price Target to $210.00

Zoetis (NYSE:ZTS) had its target price increased by equities researchers at Stifel Nicolaus from $200.00 to $210.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 7.29% from the stock’s previous close.

Several other research firms also recently commented on ZTS. BTIG Research increased their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $218.22.

Zoetis Stock Up 0.8 %

ZTS opened at $195.74 on Wednesday. The company has a market capitalization of $88.68 billion, a PE ratio of 37.71, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The business has a 50-day moving average of $183.65 and a 200-day moving average of $174.15. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.41 earnings per share. Equities research analysts forecast that Zoetis will post 5.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Zoetis

A number of institutional investors and hedge funds have recently bought and sold shares of ZTS. Hohimer Wealth Management LLC grew its position in Zoetis by 1.2% in the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after purchasing an additional 52 shares during the last quarter. Asset Dedication LLC increased its stake in Zoetis by 4.8% during the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after acquiring an additional 54 shares during the period. Angeles Wealth Management LLC raised its holdings in Zoetis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock valued at $324,000 after acquiring an additional 56 shares in the last quarter. Forza Wealth Management LLC lifted its position in shares of Zoetis by 1.8% in the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock worth $574,000 after acquiring an additional 58 shares during the period. Finally, L. Roy Papp & Associates LLP grew its holdings in shares of Zoetis by 2.8% during the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after purchasing an additional 60 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.